Evaluation of alpha-fetoprotein as a screening marker for hepatocellular carcinoma in hepatitis prevalent areas

Annals of Hepatology

Volumn 14, Issue 6, 2015, Pages 881-887

  Chun, Sejong ^a   Rhie, Su Yeon ^b   Ki, Chang Seok ^a   Kim, Jee Eun ^b   Park, Hyung Doo ^a  

^a Department of Laboratory Medicine and Genetics ^*  (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Alpha fetoprotein; Hepatocellular carcinoma; Liver cancer; Screening

Indexed keywords

ALPHA FETOPROTEIN; BIOLOGICAL MARKER; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY; AFP PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER SCREENING; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE COURSE; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN TISSUE; KOREAN (PEOPLE); LIVER BIOPSY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PREDICTIVE VALUE; PREVALENCE; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SEROLOGY; AREA UNDER THE CURVE; BLOOD; CARCINOMA, HEPATOCELLULAR; EARLY CANCER DIAGNOSIS; EVALUATION STUDY; LIVER NEOPLASMS; PATHOLOGY; PROCEDURES; REPRODUCIBILITY; SOUTH KOREA; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALPHA-FETOPROTEINS; AREA UNDER CURVE; CARCINOMA, HEPATOCELLULAR; EARLY DETECTION OF CANCER; HEPATITIS B; HEPATITIS C; HUMANS; LIVER NEOPLASMS; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PREVALENCE; REPRODUCIBILITY OF RESULTS; REPUBLIC OF KOREA; ROC CURVE;

EID: 84943144769     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.5604/16652681.1171776     Document Type: Article

References (23)

1. Jung KW, Won YJ, Kong HJ, Oh CM, Seo HG, Lee JS. Cancer statistics in Korea: incidence, mortality, survival and prevalence in 2010. Cancer Res Treat 2013; 45: 1-14.
2. Chae HB, Kim JH, Kim JK, Yim HJ. Current status of liver diseases in Korea: hepatitis B. Korean J Hepatol 2009; 15(Suppl. 6): S13-S24.
3. Kim do Y, Kim IH, Jeong SH, Cho YK, Lee JH, Jin YJ, Lee D, et al. A nationwide seroepidemiology of hepatitis C virus infection in South Korea. Liver Int 2013; 33: 586-94.
4. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology 2004; 127: 1372-80.
5. Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet 1981; 2: 1129-33.
6. Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, Nakanishi K, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993; 328: 1797-801.
7. Sherman M. Alphafetoprotein: an obituary. J Hepatol 2001; 34: 603-5.
8. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-2.
9. Ball D, Rose E, Alpert E. Alpha-fetoprotein levels in normal adults. Am J Med Sci 1992; 303: 157-9.
10. Sizaret P, Martel N, Tuyns A, Reynaud S. Mean alpha-fetoprotein values of 1, 333 males over 15 years by age groups. Digestion 1977; 15: 97-103.
11. El-Bahrawy M. Alpha-fetoprotein-producing non-germ cell tumours of the female genital tract. Eur J Cancer 2010; 46: 1317-22.
12. Liu X, Cheng Y, Sheng W, Lu H, Xu Y, Long Z, Zhu H, et al. Clinicopathologic features and prognostic factors in alpha-fetoprotein-producing gastric cancers: analysis of 104 cases. J Surg Oncol 2010; 102: 249-55.
13. Collier J, Sherman M. Screening for hepatocellular carcinoma. Hepatology 1998; 27: 273-8.
14. Sterling RK, Wright EC, Morgan TR, Seeff LB, Hoefs JC, Di Bisceglie AM, Dienstag JL, et al. Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C. Am J Gastroenterol 2012; 107: 64-74.
15. Di Bisceglie AM, Sterling RK, Chung RT, Everhart JE, Dienstag JL, Bonkovsky HL, Wright EC, et al. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol 2005; 43: 434-41.
16. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-43.
17. Chen JG, Parkin DM, Chen QG, Lu JH, Shen QJ, Zhang BC, Zhu YR. Screening for liver cancer: results of a randomised controlled trial in Qidong, China. J Med Screen 2003; 10: 204-9.
18. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004; 130: 417-22.
19. Trevisani F, D'Intino PE, Morselli-Labate AM, Mazzella G, Accogli E, Caraceni P, Domenicali M, et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol 2001; 34: 570-5.
20. Zhou L, Liu J, Luo F. Serum tumor markers for detection of hepatocellular carcinoma. World J Gastroenterol 2006; 12: 1175-81.
21. Tateyama M, Yatsuhashi H, Taura N, Motoyoshi Y, Nagaoka S, Yanagi K, Abiru S, et al. Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus. J Gastroenterol 2011; 46: 92-100.
22. El-Serag HB. Epidemiology of hepatocellular carcinoma in USA. Hepatol Res 2007; 37(Suppl. 2): S88-S94.
23. Chen L, Zhao H, Yang X, Gao JY, Cheng J. HBsAg-negative hepatitis B virus infection and hepatocellular carcinoma. Discov Med 2014; 18: 189-93.